Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Amortization of Deferred Charges (2020 - 2024)

Historic Amortization of Deferred Charges for Seres Therapeutics (MCRB) over the last 5 years, with Q3 2024 value amounting to $463000.0.

  • Seres Therapeutics' Amortization of Deferred Charges rose 1781.17% to $463000.0 in Q3 2024 from the same period last year, while for Jun 2025 it was $463000.0, marking a year-over-year decrease of 7357.31%. This contributed to the annual value of $1.4 million for FY2024, which is 2405.62% up from last year.
  • Per Seres Therapeutics' latest filing, its Amortization of Deferred Charges stood at $463000.0 for Q3 2024, which was up 1781.17% from $485000.0 recorded in Q2 2024.
  • Seres Therapeutics' 5-year Amortization of Deferred Charges high stood at $2.2 million for Q4 2021, and its period low was $118000.0 during Q1 2021.
  • Over the past 5 years, Seres Therapeutics' median Amortization of Deferred Charges value was $208500.0 (recorded in 2020), while the average stood at $375312.5.
  • Per our database at Business Quant, Seres Therapeutics' Amortization of Deferred Charges skyrocketed by 87207.21% in 2021 and then tumbled by 9295.64% in 2022.
  • Seres Therapeutics' Amortization of Deferred Charges (Quarter) stood at $222000.0 in 2020, then surged by 872.07% to $2.2 million in 2021, then plummeted by 92.96% to $152000.0 in 2022, then surged by 169.08% to $409000.0 in 2023, then increased by 13.2% to $463000.0 in 2024.
  • Its Amortization of Deferred Charges was $463000.0 in Q3 2024, compared to $485000.0 in Q2 2024 and $465000.0 in Q1 2024.